Based on 30 Wall Street analysts offering 12 month price targets to OZEM holdings in the last 3 months. The average price target is $38.61 with a high forecast of $45.36 and a low forecast of $29.97. The average price target represents a 47.92% change from the last price of $26.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","35":"$35","46":"$46","29.5":"$29.5","40.5":"$40.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45.356,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.607,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.974,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.97</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,29.5,35,40.5,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.8,28.227384615384615,29.654769230769233,31.082153846153847,32.50953846153846,33.93692307692308,35.36430769230769,36.79169230769231,38.219076923076926,39.64646153846154,41.073846153846155,42.50123076923077,43.928615384615384,{"y":45.356,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.8,27.70823076923077,28.61646153846154,29.52469230769231,30.43292307692308,31.341153846153848,32.24938461538461,33.15761538461538,34.06584615384615,34.97407692307692,35.88230769230769,36.79053846153846,37.69876923076923,{"y":38.607,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.8,27.044153846153847,27.288307692307693,27.53246153846154,27.776615384615386,28.020769230769233,28.264923076923075,28.509076923076922,28.75323076923077,28.997384615384615,29.24153846153846,29.485692307692307,29.729846153846154,{"y":29.974,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.15,"date":1704067200000,"info":"<div>Price: <b>$25<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.15,"date":1706745600000,"info":"<div>Price: <b>$25<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.15,"date":1709251200000,"info":"<div>Price: <b>$25<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.15,"date":1711929600000,"info":"<div>Price: <b>$25<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.15,"date":1714521600000,"info":"<div>Price: <b>$25<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.15,"date":1716336000000,"info":"<div>Price: <b>$25<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.61,"date":1717372800000,"info":"<div>Price: <b>$26<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.11,"date":1719792000000,"info":"<div>Price: <b>$27<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.1,"date":1722470400000,"info":"<div>Price: <b>$27<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":28.18,"date":1725321600000,"info":"<div>Price: <b>$28<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.34,"date":1727740800000,"info":"<div>Price: <b>$27<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.32,"date":1730419200000,"info":"<div>Price: <b>$27<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.8,"date":1733097600000,"info":"<div>Price: <b>$27<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$45.36

Average Price Target$38.61

Lowest Price Target$29.97

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

OZEM Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

GPCR

Structure Therapeutics, Inc. Sponsored ADR

9 Buy

0 Hold

0 Sell

Strong Buy

$89.11

xxxxxxxxxxxxxxxxxxxxxxxxxxx

KROS

Keros Therapeutics, Inc.

11 Buy

4 Hold

0 Sell

Moderate Buy

$53.33

xxxxxxxxxxxxxxxxxxxxxxxxxxx

TERN

Terns Pharmaceuticals, Inc.

5 Buy

1 Hold

0 Sell

Strong Buy

$18.38

xxxxxxxxxxxxxxxxxxxxxxxxxxx

VKTX

Viking Therapeutics

13 Buy

0 Hold

0 Sell

Strong Buy

$111.40

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ALT

Altimmune

6 Buy

0 Hold

0 Sell

Strong Buy

$22.00

OZEM Stocks With Highest Downside Potential

No stocks with downside potential were found for this ETF

Please check back later or explore other ETFs for potential investment opportunities.

OZEM ETF FAQ

What is OZEM’s average 12-month price target, according to analysts?

Based on analyst ratings, OZEM’s 12-month average price target is $38.61.

What is OZEM’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for OZEM, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OZEM a Buy, Sell or Hold?

OZEM has a consensus rating of Moderate Buy which is based on 23 buy ratings, 6 hold ratings and 1 sell ratings.

What is OZEM’s price target?

The average price target for OZEM is $38.61. This is based on 30 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $45.36 ,the lowest forecast is $29.97. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about OZEM?

OZEM’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 30 Wall Streets Analysts.

How can I buy shares of OZEM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing